clinical trial · NCT05763082
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
Plaque Psoriasisroflumilast cream 0.3%ZoryvePlacebo
brief summary
To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
started
Feb 7, 2023
primary completion
Aug 8, 2023
completion
Aug 8, 2023
last updated
Aug 12, 2024
official title
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis' Roflumilast Cream 0.3% to Arcutis's Zoryve™ (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol